23948sdkhjf

Krönika: Collaboration across borders

| Av Sarah Lidé och Petter Hartman, MVA | Tipsa redaktionen

The life science industry is undergoing a period of transition worldwide. Pricing pressures by healthcare systems who are under cost pressures themselves due to ageing populations and the rise of chronic diseases, technological changes towards biopharmaceuticals and personalised therapies, sector disruption driven by digitalisation with technologies such as artificial intelligence and big data, alongside rising rates of engagement by patients who desire greater knowledge about and influence over their treatments, are just some of the trends affecting the life science sector globally. Furthermore, across all industries, competition in terms of talent, investment, trade and technological development is intensifying.

Läs också: EU satsar på barnlöshet

Against this backdrop, countries are not standing still – nations such as the UK have been explicit with their ambition to strengthen the development and growth of national life science industries. The same applies to Scandinavia – Denmark now has an internationalisation strategy for health and the life sciences, and the Swedish government recently presented an eight-point national life science strategy. While there are many common points of interest in the two countries’ ambitions and their choice of strategic areas, there are also certain important differences. In Denmark, the focus is clearly set on generating growth, and internationalisation and exports are keywords. The Swedish debate centres more on co-operation, and partnerships between private, public and academic actors are among the principal elements. The Swedish strategy also highlights the potential for a broader Nordic collaboration to contribute to regional competitiveness within life science, which makes sense given that the Nordic countries share many of the same challenges within the sector.

With this in mind, Medicon Valley (the life science cluster based in the Öresund region that spans the Capital Region of Denmark and Region Zealand in Denmark, and the region of Skåne in Sweden) has an important part to play in both Danish and Swedish strategies. The region employs 58% of those working in life science in Denmark and Sweden combined, making it Scandinavia’s leading life science region and showcasing the strength of collaborating across the border.

Similar strengths exist within the regional research environment, which is a particularly important building block for the development of a life science cluster like Medicon Valley. A strong research environment can serve to attract companies and talents, and generate new ideas and innovations. 54% of Medicon Valley’s scientific publications between 2006 and 2016 arose from international collaboration, and such international collaborations has led to significantly more citations than publications resulting from national collaborations or the work of individual research groups.

However, transborder collaboration has definite room for improvement. Research networks in Medicon Valley are still predominantly national, signalling that there are certain structures that favour national collaborations, for example national education and research structures, with grants often national in nature. We believe that there are synergies to be won in strengthening cross-border collaboration, particularly in Scandinavia with a shared culture as well as proximity to a strong ecosystem of industry, academia and healthcare actors.

Given that Denmark and Sweden jointly combined contributed to 3.7% of global life science exports in 2018, the two countries can be likened to small vessels navigating in a big sea, that is in turn facing turbulent times. There are therefore definite advantages to be had in adopting a joint Scandinavian face towards global markets, harnessing the strengths and resources of both nations to create a multiplier effect generated by regional synergies. We see three concrete steps that could be taken towards this end.

With the two nations adopting a stronger and more strategic focus with the development of national life science strategies, this could be taken one step further by identifying common areas of strength, and collaborating around shared challenge-driven platforms through research and innovation, in order to create a stronger international profile for both countries. These areas can include reproductive health, oncology, CNS and diabetes, which are already established scientific strongholds in Medicon Valley, and can be further complemented by developments in other regionally strong sectors (such as ICT, mobility and food). A challenge-driven, multi-disciplinary and cross-sectoral approach to research and innovation can provide the conditions to thrive in an increasingly complex environment.

Creating joint bi-national funding mechanisms can enable a more focused and aligned mechanism for collaboration within the triple helix (industry, academia and government), thus bringing the best resources and talent from both sides of the border to address an issue of strategic importance to the region.

A good example of this is the ReproUnion cross-border public-private initiative, which aims to address involuntary infertility and reproductive diseases. To overcome the challenge associated with national funding mechanisms, ReproUnion has adopted a joint financing model, where a common funding platform grants resources to projects which aim to combat infertility. This joint funding platform requires that the various regional partners within Medicon Valley are together responsible for assessing potential projects and related issues. This ensures that priorities and interests within the partnership are aligned towards common goals, thus combating fragmentation and the pursuit of special interests.

ReproUnion shows the potential of having a more coordinated approach from the Danish and Swedish life science offices in increasing the flexibility of funding mechanisms to encourage a cross-border approach to research and innovation, including supporting startups and micro-enterprises within life science.

Given how digitalisation is transforming both the healthcare and life science sectors, data will increasingly be the new currency of choice in determining the attractiveness of countries as a base for research and innovation. The Swedish national life science office has explicitly mentioned the better utilisation of health and clinical data as a key priority area, and we see value in exploring opportunities for aligning this ambition and Swedish health data assets (health registers, clinical databases and biobanks) with our Danish counterparts (such as the “Data Saves Lives” initiative, which also aims to ensure the better use of Danish health data), to provide enhanced data volumes for the conducting of research. This will require a coordinated approach to the treatment of and access to data to ensure that data security and personal integrity is maintained, while also serving to propel the development of personalised treatments and therapies that will benefit patients in both countries.

Medicon Valley, with its strong university environments and deep research traditions, innovative companies, large and small, and high-quality healthcare systems, all located in a small geographic radius, shows how strong we can be together, if borders become less of a barrier and we see instead the benefits of adopting a transnational perspective towards industry, research and growth in Denmark and Sweden.

We look forward to furthering the conversation on how the two nations can take steps towards this at the upcoming The Future of the Danish and Swedish Life Science conference, where Petter will be a part of a panel discussion addressing this important topic.

Mer om: MVA
Håll dig uppdaterad med Life Science Sweden

Jag accepterar Nordiske Mediers villkor och avtal

Är du prenumerant? Bli prenumerant

Med en prenumeration får du obegränsad tillgång till webbtidningen. Läs webbtidningen online.

Kommentarer (0)

JOBB I FOKUS

Startsidan just nu

Life Science Sweden tar sommarledigt

Vi på redaktionen går på semester och är tillbaka den 3 augusti. Vi hoppas att ni får en riktigt trevlig sommar! 

Jobb & karriär
Flera förändringar i Oncopeptides ledning

Rockad och nyrekrytering karaktäriserar bolagets tillsättning av ny vd samt forskningschef.

Regeringen tillsätter coronakommission

Rekordmånga läser Life Science Sweden

Intresset för tidningen har ökat kraftigt. Under våren har antalet besökare tredubblats.

Finans
Lipigons nyemission övertecknad

Nyhetsbrev

Studie: Fler skulle kunna vara immuna mot covid-19

Preliminära resultat pekar på att fler kan vara immuna mot covid-19, även om de fått negativt antikroppssvar.

Arkiv

Gileads besked – så mycket kommer remdesivir kosta

Priset för att behandla en covid-19-patient med remdesvir landar på 21 800 kronor. – Det är lite lägre än vad jag trodde, säger Anders Sönnerborg till Life Science Sweden.

2

Krönika
Torgny Fornstedt: Analytisk kemi måste hitta tillbaka till sina rötter

Det behövs fler kunniga analytiska kemister både på universiteten och inom industrin, skriver Torgny Fornstedt i en krönika.

Keminyheter
Sverige vill ha en EU-gemensam kemikaliestrategi

Lovande resultat för oral terapi vid atopiskt eksem

Jobb & karriär
Mattias Bergqvist ny ledamot i Scandinavian CRO

2

Ledare
Samuel Lagercrantz: Bergström bra val som vaccinsamordnare

Valet av Richard Bergström som vaccinsamordnare för covid-19 är glädjande, skriver Life Science Swedens chefredaktör Samuel Lagercrantz i en kommentar till gårdagens besked.

Atrogi får anslag för fetmaforskning

Forskningsföretaget Atrogi har fått ett anslag från Eurostar för utveckling av en substans mot fetma.

LSS in English
Marie Gårdmark: Do EMA and FDA talk to each other?

Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.

Remdesivir på väg mot EU-godkännande

Det europeiska läkemedelsverket EMA:s vetenskapliga kommitté rekommenderar remdesivir för godkännande för behandling av covid-19.

Finans
Aegirbio debuterar på Nasdaq First North

Stor genomslagskraft för immunterapi i Sverige

Internationell uppståndelse kring Tegnells sommarprat

Utländska medier har uppmärksammat Anders Tegnells uttalande där han beskriver andra länders agerande kring coronapandemin som ”galenskap”.

Keminyheter
Rötter och grenar blir vårdkläder

2

Tom Britton: ”Nivån för flockimmunitet är lägre än vad vi trott”

Nya matematiska modeller pekar på att flockimmunitetsnivån är kraftigt lägre än vad man tidigare trott, och att immuniteten i dagsläget spelar en större roll, enligt en ny rapport.

Vitalis blir digital konferens

Jobb & karriär
Maja Johansson blir chef för nya vaccinanläggningen i Umeå

Sedan en månad tillbaka är Maja Johansson ny site manager för Diamyd Medicals nya tillverkningsenhet i Umeå.

Remdesivir ges till barn med covid-19 i ny studie

Finans
Avgiften för klinisk läkemedelsprövning ökar med 250 procent

Ansökningsavgiften för kliniska prövningar höjs från 50 000 kronor till 123 000–148 000 kronor till följd av en ny EU-förordning, enligt rapport från Läkemedelsverket.

Selectimmune rekryterar ny vd

Tillväxtanalys ska bevaka life-science industrins utveckling

Vinnova stödjer KTH:s testkit för antikroppar mot covid-19

Jobb & karriär
Abigo nyanställer

Elektas vd avgår med omedelbar verkan

Ansiktsmask krävs för covidskydd enligt Science-artikel

Jobb & karriär
Cellavision tappar vd

Keminyheter
Kemikalieinspektionen i topp i arbetsplatsranking

1

Apotea och Werlabs säljer antikroppstest för covid-19

Läkemedelsverket förbjuder ett till covidtest

Röntgen visar hur coronaviruset förökar sig

Jobb & karriär
Micropos får ny vd

Se alla Medlemsnytt

Cobra signs supply agreement with AstraZeneca

Ny medarbetare till PharmaRelations i Norge

PharmaRelations stärker upp med ny konsultchef

Join us for a webinar on confocal microscopy!

3D Scanning Systems - Innovative Solutions for 3D digitizin

Akut produktion av desinfektionsmedel med hjälp av Busch

Improve your metrology skills, also @home.

Leverans av Busch vakuumsystem till Brasilien

Cleaning and Disinfecting Microscope and Optical Components

Busch Vakuum Solutions levererar till sjukhus i Palestina

Are you working from home?

Busch Vacuum Solutions levererar till sjukhustrailers i USA

Centralisering av vakuum från Busch Vacuum Solutions

Increase efficiency in the lab!

Verifiering vid tillverkning av Ventilatorer

Busch levererar vakuumsystem till akutsjukhus i Madrid

Samarbete mellan Busch i Schweiz och Frankrike mot Corona

Rening av gaser med vakuumteknik från Busch Vacuum Solutions

Optimize measurement plans remotely with free ZEISS CALYPSO

Find what you need from the ZEISS Industrial Quality world.

Biofiltrering med Busch TYR Blåsmaskin

Ny Country Manager PharmaRelations Norge

Perfekt packad skinka med vakuum från Busch

Last week, we introduced ZEISS Lightsheet 7.

Fiskodling med vakuum från Busch Vacuum Solutions

Sänd till en kollega

0.11